Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$317.60
▼ $1.27 (-0.4%)
Market data updated: 09/19 01:57 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$12.51B
Day Range
$317.50 - $318.90
52-Week Range
$221.26 - $362.41
Beta
—
Next Earnings
03.11.2026
Support
$315.69
Resistance
$328.60
PEN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+24.4% (1Y)
Strengths: 9/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 1155.6%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $99.40 vs. price $317.60 (-68.7%)
Fair Value
Signal tension
Growth scores strong (76/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
51
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
76
Quality
58
Value
33
Momentum
16
Risk
56
Sentiment
86
Fundamental
68
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Penumbra, Inc. has primarily focused on **stock valuation comparisons** with rival TFX (Terumo Medical Corporation) in August 2026, where analysts debated which company offered better investment value. Additionally, the company faced a **patent infringement lawsuit** filed by Incuvate, LLC in late August 2026, alleging violations in the U.S. District Court for the Northern District of California. No other substantive details about Penumbra’s operations or recent developments were explicitly mentioned in the provided sources.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Penumbra, Inc.. News trend score: 86. Reason: 7 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
29
🎯 Conviction (vs. Emotion)
41
Psychology
80
Fundamentals
68
Technical
16
Valuation
33
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+1%
Market Narrative
70
Fundamental Reality
41
Narrative Gap
+29
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant anchoring behavior suggests traders are fixating on the 1.1% proximity to support, ignoring the stock’s extreme valuation (+221% above DCF) and fundamental outperformance. Overconfidence (score 45) may stem from misaligned price-action and earnings growth, while the wide narrative gap (33) hints at a disconnect between market perception and fundamentals. The key question: will traders break from anchoring if support holds, or will overconfidence persist despite valuation mispricing? The low FOMO/Panic scores (10/11) imply no urgency, but the overconfidence signal could trigger a correction if fundamentals fail to justify the premium.
Updated: 09/09/2026, 07:05 AM
What could change this?
👥 What the crowd believes
"TFX vs. PEN: Which Stock Is the Better Value Option?"
"a strategic acquirer would see a unique technology at a strong price"
"Incuvate, LLC filed patent-infringement lawsuit against Penumbra"
"raising target price to $357.00"
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Benjamin Graham — 18/100
🗣️ Why do they disagree?
The stark contrast between the methodologies reflects a deep divide between those who prioritize fundamental strength and growth potential versus those skeptical of valuation or market positioning. Bagehot, Housel, and Nelson all score near-perfectly, emphasizing liquidity, patient compounding, and cyclical undervaluation—suggesting this stock aligns with defensive resilience, long-term patience, or tactical timing. In contrast, Graham’s rigid defensive framework and Livermore’s trend-following rules deliver the lowest scores, flagging it as either structurally weak or out of sync with market momentum. Meanwhile, Fisher and Veblen’s middling scores highlight uncertainty over profitability and quality, while Marks’ caution and the efficient-market skeptics’ indifference underscore valuation and behavioral concerns. The debate hinges on whether the stock’s perceived growth or liquidity justifies ignoring red flags like valuation or trend weakness.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 100
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 91
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 88
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 78
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 64
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 64
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 64
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 63
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 59
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 49
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 44
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 39
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 21
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 18
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 9 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a trading range, but the picture isn't yet clear enough on the likely direction.
Low confidence
$315.69
Range Bottom
$328.60
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
67.1%
Operating Margin
13.5%
Net Margin
12.7%
EBITDA Margin
14.7%
ROE
12.4%
ROA
9.7%
ROIC
—
EPS
$4.57
Cash
$186.90M
Total Debt
—
Current Ratio
6.64
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$317.60
Estimated Fair Value (DCF)
$99.40
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-68.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
18.4%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 18.4% | $207.19M | $190.08M |
| 2 | 14.5% | $237.13M | $199.59M |
| 3 | 10.5% | $261.95M | $202.28M |
| 4 | 6.5% | $278.94M | $197.61M |
| 5 | 2.5% | $285.91M | $185.82M |
Base FCF (last actual year)
$174.93M
Terminal Value
$4.51B
Present Value of Terminal Value
$2.93B
Enterprise Value
$3.91B
Net Debt
$0
Equity Value
$3.91B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$36.33
Tangible Book Value per Share (Tangible NAV)
$31.93
Sentiment based on basic keywords (not AI) — 7 positive, 12 neutral, 1 negative out of the last 20 articles.
Yahoo · 16.9.2026
Zacks · 11.9.2026
Yahoo · 11.9.2026
Yahoo · 26.8.2026
Zacks · 26.8.2026
Benzinga · 25.8.2026
Yahoo · 14.8.2026
Trefis · 14.8.2026
Zacks · 10.8.2026
Yahoo · 10.8.2026
Zacks · 6.8.2026
Yahoo · 6.8.2026
Morningstar Research · 5.8.2026
Argus Research · 4.8.2026
Associated Press · 30.7.2026
Yahoo · 30.7.2026
PR Newswire · 30.7.2026
Benzinga · 30.7.2026
Simply Wall St. · 26.7.2026
Yahoo · 26.7.2026
Penumbra, Inc. (PEN) currently has a StockIQ AI score of 51/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
PEN currently scores 51/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, PEN's estimated fair value is $99.40, which is 68.7% below the current price of $317.60. This is one valuation model among several signals in the fair-value category, not a price target.
PEN's technical score is 16/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 1155.6%; Net income growth: 1168.1%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Estimated fair value: $99.40 vs. price $317.60 (-68.7%); Calmar: 0.17 (3y annualized return 6.7% / max drawdown 40.1%); Price is below the 50-day average.
StockIQ has no recorded dividend payment history for PEN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 4 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Narayan Shruthi | Grant/Award from Employer | 17.8.2026 | 3,060 | +3,060 | — |
| Elsesser Adam | Gift | 19.5.2026 | 77,000 | -77,000 | — |
| Elsesser Adam | Gift | 19.5.2026 | 683,042 | -77,000 | — |
| Grewal Harpreet | Open Market Sale | 2.4.2026 | 100 | -100 | $328.22 |
| Grewal Harpreet | Open Market Sale | 2.4.2026 | 8,719 | -100 | $328.22 |
| Roberts Johanna | Tax Withholding in Shares | 15.3.2026 | 186 | -186 | $336.18 |
| Yuen Maggie | Tax Withholding in Shares | 15.3.2026 | 186 | -186 | $336.18 |
| Narayan Shruthi | Tax Withholding in Shares | 15.3.2026 | 117 | -117 | $336.18 |
| Shiu Lambert | Tax Withholding in Shares | 15.3.2026 | 150 | -150 | $336.18 |
| Roberts Johanna | Tax Withholding in Shares | 15.3.2026 | 67,298 | -186 | $336.18 |
| Yuen Maggie | Tax Withholding in Shares | 15.3.2026 | 18,167 | -186 | $336.18 |
| Shiu Lambert | Tax Withholding in Shares | 15.3.2026 | 39,323 | -150 | $336.18 |
| Narayan Shruthi | Tax Withholding in Shares | 15.3.2026 | 30,755 | -117 | $336.18 |
| Yuen Maggie | Open Market Sale | 2.3.2026 | 2,432 | -2,432 | $342.30 |
| Yuen Maggie | Open Market Sale | 2.3.2026 | 18,353 | -2,432 | $342.30 |
| Roberts Johanna | Grant/Award from Employer | 17.2.2026 | 2,630 | +2,630 | — |
| Roberts Johanna | Grant/Award from Employer | 17.2.2026 | 67,484 | +2,630 | — |
| Yuen Maggie | Grant/Award from Employer | 17.2.2026 | 20,785 | +2,630 | — |
| Shiu Lambert | Grant/Award from Employer | 17.2.2026 | 39,473 | +2,300 | — |
| Narayan Shruthi | Grant/Award from Employer | 17.2.2026 | 30,872 | +2,630 | — |
| Roberts Johanna | Tax Withholding in Shares | 15.2.2026 | 482 | -482 | $339.30 |
| Roberts Johanna | Tax Withholding in Shares | 15.2.2026 | 64,854 | -482 | $339.30 |
| Yuen Maggie | Tax Withholding in Shares | 15.2.2026 | 18,155 | -481 | $339.30 |
| Shiu Lambert | Tax Withholding in Shares | 15.2.2026 | 37,173 | -412 | $339.30 |
| Narayan Shruthi | Tax Withholding in Shares | 15.2.2026 | 28,242 | -705 | $339.30 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,731,493 shares short as of 2026-08-31 · vs. 1,836,046 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
52.7% of trading volume this week was short selling, vs. 64.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology